Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 325-328

  Davies, Michael M ^b   Johnston, Patrick G ^c   Kaur, Suki ^b   Allen Mersh, Timothy G ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTERY CATHETERIZATION; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLOXURIDINE; HEPATIC ARTERY; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); THYMIDYLATE SYNTHASE;

EID: 0033009501     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Allen-Mersh, T. G., Earlam, S., Fordy, C., Abrams, K., and Houghton, J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet, 344: 1255-1260, 1994.
2. Burke, D., Fordy, C., Earlam, S., and Allen-Mersh, T. G. Hepatic arterial cannulation should be avoided in patients with >1 liter liver metastasis volume. Br. J. Cancer, 75: 1213-1216, 1997.
3. Pinedo, H. M., and Peters, G. F. J. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664, 1988.
4. Durand-Zaleski, I., Earlam, S., Fordy, C., Davies, M. M., and Allen-Mersh, T. G. Cost-effectiveness of systemic and regional chemotherapies for unresectable colorectal liver metastases. Cancer (Phila.), 83: 882-888, 1998.
5. Davis, S. T., and Berger, S. H. Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2′-deoxyuridine. Mol. Pharmacol., 43: 702-708, 1993.
6. Jenh, C. H., Geyer, P. K., Baskin, F., and Johnson, L. F. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol. Pharmacol., 28: 80-85, 1985.
7. Copur, S., Keisuke, A., Drake, J. C., Allegra, C. J., and Chu, E. Thymidylate synthase gene amplification in human cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol., 49: 1419-1426, 1995.
8. Chu, E., Drake, J. C., Koeller, D. M., Zinn, S., Jamis-Dow, C. A., Chao Yeh, G., and Allegra, C. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol. Pharmacol., 39: 136-143, 1991.
9. Beck, A., Etienne, M. C., Cheradame, S., Fishel, J. L., Formento, P., Renee, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer, 30A: 1517-1522, 1994.
10. Peters, G. J., van der Wilt, C. L., and van Groeningen, C. J. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur. J. Cancer, 30A: 1408-1411, 1994.
11. Moran, R. G., Spears, C. P., and Heidelberger, C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc. Natl. Acad. Sci. USA, 76: 1456-1460, 1979.
12. Johnston, P. G., Liang, C-M., Henry, S., Chabner, B. A., and Allegra, C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res., 51: 6668-6676, 1991.
13. Larsson, P-A., Carlsson, G., Gustavsson, B., and Spears, C. P. Thymidylate synthase in advanced gastrointestinal and breast cancers. Acta. Oncol., 35: 469-472, 1996.
14. Johnston, P. G., Lenz, H-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
15. Horishoki, T., Danenberg, K. D., Stadbauer, T. H. W., Volkenandt, M., Shea, L. C. C., Aigner, K., Gustavsson, B., Leichman, L., Frosing, R., Ray, M., Gibson, N. W., Spears, C. P., and Danenberg, P. V. Quantitation of thymidylate synthase, dihydroreductase and DT-diaphorose gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52: 108-116, 1992.
16. Leichman, L., Lenz, H-J., Leichman, C. G., Goshen, S., Danenberg, K., Baranda, J., Spears, S. P., Boswell, W., Silberman, H., Ortega, A., Stain, S., Beart, R., and Danenberg, P. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer, 31A: 1306-1310, 1995.
17. Hayward, J. L., Carbone, P. P., Heuson J-C., Kumaoka, S., Segaloff, A., and Rubens, R. D. Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer, 13: 89-94, 1977.
18. Buroker, T. R., O'Connell, M. J., Wieand, S., Krook J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., and Gesme, D. H. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol., 12: 14-20, 1994.
19. Dworkin, M. J., Burke, D., Earlam, S., Fordy, C., and Allen-Mersh, T. G. Measurement of response to treatment in colorectal liver metastases. Br. J. Cancer, 71: 873-876, 1995.
20. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
21. Altman, G. D. Fisher's exact test. In: Practical Statistics for Medical Research, pp.253-257. London: Chapman and Hall, 1991.
22. Peto, R., Pike, M. C., and Armitage P. Design and analysis of randomized clinical trials requiring prolonged observations. Br. J. Cancer, 35: 1-39, 1977.
23. Kaplan, E. L., and Meier P. Nonparametric estimations for incomplete observations. J. Am. Stat. Assoc., 53: 448-457, 1958.
24. O'Connell, M. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer (Phila.), 63: 1026-1030, 1989.
25. Mulder, N. H., Timmer-Bosscha, H., Meerssma, G. J., and Verschueren, R. C. J. Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer. Anticancer Res., 14: 2677-2688, 1994.
26. Fordy, C., Glover, C., Davies, M. M., Allen-Mersh, T. G. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br. J. Cancer, 78: 1058-1060, 1998.
27. Xiong, Y. P., Danenberg, K., Metzger, R., Salonga, D., Groshen, S., Danenberg, P., Davies, M. M., Allen-Mersh, T. G., and Lenz, H-J. Thymidylate synthase (TS) mRNA levels predict for survival and response to hepatic artery infusion (HAI) with FUDR in patients with colorectal liver metastases. Proc. ASCO, 16: 258a, 1997.
28. Peters, G. J., van der Wilt, C. L., van Triest, B., Codacci-Pisanelli, G., Johnston, P. G., van Groeningen, C. J., and Pinedo, H. M. Thymidylate synthase and drug resistance. Eur. J. Cancer, 31A: 1299-1305, 1995.
29. Sigurdson, E. R., Ridge, J. A., and Daly, J. M. Fluorodeoxyuridine uptake by human colorectal hepatic metastases after hepatic artery infusion. Surgery, 100: 285-291, 1986.
30. Ensminger, W. D., Rosowsky, A., Raso, V., Levin, D. C., Glode, M., Come, S., Steele, G., and Frei, E. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res., 38: 3784-3792, 1978.
31. Zhang, Z-G., Harstrick, A., and Rustum, Y. M. Mechanisms of resistance to fluoropyrimidines. Semin. Oncol., 19 (Suppl. 3): 4-9, 1992.